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mental scores or work productivity. Greater increases in pharmacy costs for the DTM 
cohort were partially offset by smaller increases in medical costs, resulting in similar 
total health care costs for DTM patients compared with controls.
ME2
THE EFFECT OF MEDICARE PART D PRESCRIPTION DRUG COVERAGE 
GAP ON MEDICATION ADHERENCE
Said Q, Li C, Souder E, Hastings JK
University of Arkansas for Medical Sciences, Little Rock, AR, USA
OBJECTIVES: To investigate the impact on medication adherence for patients with 
common chronic conditions who reach the Medicare Part D coverage gap versus those 
who do not. The study is unique because it included characteristics of Medicare Part-D 
enrollees that are typically not available in administrative databases. METHODS: A 
survey based on the Seniors’ Prescription Coverage, Use and Spending Survey and the 
Brief Medication Questionnaire was distributed to elderly persons seeking care at the 
pharmacies within the University of Arkansas for Medical Sciences Advanced Practice 
Network. Patients recruited were ≥65 years, enrolled in Medicare Part D in 2007 or 
2008, and had the following conditions: hypertension, hyperlipidemia, diabetes, 
asthma/COPD, or depression. Adherence was a composite measure based on responses 
to several questions asking if subjects skipped doses, took smaller doses or decided to 
not ﬁll at all. Logistic regression was run to evaluate the impact of being in coverage 
gap on medication adherence, adjusting for age, sex, race, income, and education 
levels. RESULTS: A total of 152 subjects (62% female, 44.1% greater than 75 years 
of age, and 92.7% white) completed the survey. A total of 44.7% reached coverage 
gap in 2007 or 2008 and 31.6% reported non-adherent. 45.4% had monthly income 
of $2000 or less and 34.2 had no college education. Subjects in the coverage gap were 
twice as likely to be non-adherent to medication regimen as compared to those not in 
the gap (adjusted odds ratio = 2.07, p-value = 0.051). CONCLUSIONS: There is likely 
signiﬁcant impact of falling in the coverage gap on medication adherence for the 
elderly, which may have adverse health consequences. Decision makers ought to be 
cognizant of these implications.
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OBJECTIVES: Patients with depression may not respond to ﬁrst-line antidepressant 
(AD) therapy. Treatment options include changing from one AD to another and 
augmenting AD treatment with another concurrent AD, a stimulant, a mood stabilizer, 
or a second generation antipsychotic (SGA). While treatment decisions are primarily 
based on clinical considerations, they may also be inﬂuenced by patient cost-sharing. 
This study examines the relationship between cost-sharing and the use of augmenta-
tion among depressed patients who are already ﬁlling prescriptions for AD treatment. 
METHODS: Patients aged 18–64 in employer-sponsored plans with a diagnosis of 
depression and at least one antidepressant prescription were found in the 2004–2008 
MarketScan Database. Twelve months of continuous medical and prescription cover-
age were required before and after the initial antidepressant prescription. Patients with 
certain psychiatric diagnoses (e.g., schizophrenia) were excluded, resulting in a sample 
of 48,865 patients. Logistic regression models estimated the probability of augmenta-
tion within 12 months as a function of a plan-level cost-sharing index for brand and 
generic antidepressant and augmentation medications, controlling for demographic 
and clinical characteristics. Results are reported as odds ratios (OR) and 95% conﬁ-
dence intervals (CI). RESULTS: A $10 increase in the cost-sharing index for all 
augmentation classes was associated with a 5% decrease in the odds of any augmenta-
tion (OR 0.947, 95% CI 0.916–0.979, N = 48,795). A $10 increase in the cost-sharing 
index for antidepressants was associated with a 6% decrease in the odds of augmenta-
tion with a second antidepressant (OR 0.939, 95% CI 0.902–0.977, N = 47,269). 
CONCLUSIONS: Prescription drug cost-sharing appears to inﬂuence the decision to 
augment AD treatment. Financial barriers may prevent patients from receiving addi-
tional care.
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OBJECTIVES: To examine, using nationally representative data, the impact of Medi-
care Part D on out-of-pocket-costs, emergency room visits, hospitalization, and 
general health among civilian non-institutionalized Medicare beneﬁciaries. 
METHODS: The primary data were from the Medical Expenditure Panel Survey 
(MEPS) panel 10 data, which included Medicare beneﬁciaries aged 65 and older in 
2005. Near elderly respondents in MEPS (aged 55 to 63 years old) in 2005 served as 
control subjects. Raw and adjusted difference-in-differences were used to identify the 
effects of Medicare Part D on Medicare beneﬁciaries in terms of out-of-pocket costs, 
emergency room visits, hospitalization, and general health according to a preference-
based summary score (SF-12 based utility scores). RESULTS: Controlling for secular 
trends, Medicare Part D prescription drug beneﬁt resulted in a 22% (95% CI: 
7%–37%) reduction in out-of-pocket costs among Medicare beneﬁciaries (p = 
0.0020). However, the Medicare Part D beneﬁt did not signiﬁcantly impact emergency 
room visits (OR = 1.15, 95%CI: 0.59–1.71), hospitalization (OR = 1.64, 95% CI: 
0.68–2.60), or overall health (β = −0.0057, 95% CI: −0.0210–0.0096) among Medi-
care beneﬁciaries compared to controls. CONCLUSIONS: In the ﬁrst year following 
the implementation of Medicare Part D, out-of-pocket costs for prescription drugs 
were reduced among Medicare beneﬁciaries. However, Medicare Part D was not 
associated with improved health outcomes of Medicare beneﬁciaries as measured by 
reductions in emergency room visits and hospitalization and improvement in their 
health utility score. Further research should follow Medicare beneﬁciaries for a longer 
period of time after its implementation or focus on beneﬁciaries with diseases that 
might be more sensitive to Medicare Part D.
PODIUM SESSION II: STUDIES DEALING WITH SELECTION BIAS
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OBJECTIVES: To compare the incremental medical expenditure associated with alter-
native disease modifying anti-rheumatoid drug (DMARDs) choices in Rheumatoid 
Arthritis. METHODS: Retrospective cohorts were constructed from California Med-
icaid paid insurance claims between January 1, 1998 to December 31, 2005. Non-
overlapping monthly panels were created from pharmacy claims for biologic 
(adalimumab and etanercept) and standard (methotrexate, leﬂuonomide, hydroxy-
chloroquine and sulfasalazine) DMARDs. Final sample included 59,788 observations 
on 7,025 patients. Covariates included age, gender, race, location of beneﬁciary’s 
county in either Northern or Southern California, population density in beneﬁciaries 
county, exclusive fee-for-service reimbursement used in beneﬁciary’s county, Medicare 
and Medicaid dual eligibility, Charlson comorbidities index excluding Rheumatoid 
arthritis, and expenditures associated with pharmacy, out-patient, inpatient, inpatient-
MD, LTC, and ER visits in the 3-months prior to treatment. We compared parameter 
estimates between naïve ﬁxed effects (FE) and instrumental variables based ﬁxed 
effects (IV-FE) panel data models. First lag of the observed treatment served as the 
instruments for the endogenous variables in IV-FE models to mitigate time-varying 
endogeneity. The primary dependant variable was total monthly expenditure. Second-
ary analysis included monthly expenditures associated with pharmacy, out-patient, 
inpatient, inpatient-MD, LTC, and ER visits. RESULTS: Based on the FE model, as 
compared to methotrexate, incremental monthly total expenditure associated with 
adalimumab ($1623.4, p < 0.001), etanercept ($1185.3, p < 0.001) and leﬂunomide 
($467.3, p < 0.001) was signiﬁcantly higher. Based on the IV-FE model, total expen-
diture associated with adalimumab ($2129.9, p < 0.001), etanercept ($1604.1, p < 
0.001) and leﬂunomide ($686.8, p < 0.001) exhibited signiﬁcant increase in magnitude 
of the parameter estimates, again with baseline as methotrexate. Under identiﬁcation 
test based on Anderson’s canonical correlation LM statistic, strongly rejected the null 
hypothesis in all the IV-FE models. CONCLUSIONS: The incremental acquisition cost 
associated with adalimumab, etanercept and leﬂunomide may not be offset by com-
mensurate reductions in routine and catastrophic resource utilization in the California 
Medicaid population.
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OBJECTIVES: Propensity scores (PS) are often used with the binary treatments. 
However, in day to day practice multiple treatment settings are experienced rather 
than binary treatments. Therefore extension of binary PS analysis to multiple PS will 
add to the empirical knowledge of use of PS. We compared binary PS analysis with 
multiple PS approach by examining clinical effectiveness in patients with Chronic 
Heart Failure (CHF). METHODS: The study was a retrospective analysis of a national 
cohort of patients diagnosed with CHF identiﬁed from the Department of Veterans 
Affairs electronic medical records system. PS analysis (binary and multiple) was used 
to balance 47 baseline patient characteristics between the different Angiotensin Con-
verting Enzyme Inhibitors (ACEIs). For multiple PS we used multinomial logistic 
regression and for binary PS we split our cohort into separate models. Effect of dif-
ferent ACEIs on time to death was assessed using a multiple PS weighted Cox pro-
portional hazard model and three separate binary PS weighted Cox proportional 
hazard models. Captopril was used as reference in all models. The statistical signiﬁ-
cance of effect of individual ACEIs on mortality was compared between the two 
propensity approaches. RESULTS: For binary propensity approach the adjusted 
hazards ratio from three different PS-weighted Cox models were 1.003 (95% CI: 
0.724–1.390) for enalapril, 0.740 (95% CI: 0.688–0.796) for fosinopril and 0.823 
(95% CI: 0.770–0.879) for lisinopril compared with captopril. For multiple propensity 
approach the adjusted hazards ratio were 1.033 (95% CI 0.739–1.445) for enalapril, 
0.738 (95% CI: 0.685–0.796) for fosinopril, and 0.819 (95% CI: 0.767–0.875) for 
lisinopril. CONCLUSIONS: We found the 2 propensity approaches produced similar 
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estimates of the effects of individual ACEIs on mortality. Multiple PS may be used 
more often if no information needed to predict outcomes is lost from sub sampling.
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METHODS IN ELDERLY ANTIPSYCHOTIC USERS
Mehta S, Chen H, Johnson M, Aparasu RR
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OBJECTIVES: Various propensity score matching techniques are used in observa-
tional studies to reduce selection and confounding bias. The purpose of this study was 
to evaluate the four most popularly used matching methods namely Mahalanobis 
metric matching within calipers of propensity scores, caliper matching with and 
without replacement and greedy matching for making elderly antipsychotic users 
comparable. METHODS: IMS LifeLink™ Claims were utilized to identify elderly 
patients using atypical and typical antipsychotics. Eighty covariates including demo-
graphics, hospitalization, co-morbidities and co-medications were used to match 
typical and atypical antipsychotic users using propensity scores matching. Propensity 
matching methods were evaluated on the basis of following criteria: (1) Number of 
variables which remains signiﬁcant after matching using t-test and chi-square; (2) 
Percentage bias reduction for the variables which remained signiﬁcant after matching; 
(3) Mean difference in propensity scores as a percentage of average standard deviation 
(SD); and (4) Density estimates of the propensity scores of the two groups using the 
Kolmogorov-Smirnov test. RESULTS: The four matching methods reduced bias by 
making two groups comparable. However greedy matching yielded the best results 
when the four criteria were applied. Only 5 explanatory variables remained signiﬁcant 
after greedy matching compared to 36, 43 and 9 with Mahalanobis metric matching, 
and caliper matching with and without replacement, respectively. More than 90% 
bias reduction was obtained through all the matching methods. Mean difference as a 
percentage of the average SD was 0% with greedy and caliper matching with replace-
ment and these were the only techniques that produced propensity scores densities 
with insigniﬁcant differences. CONCLUSIONS: The greedy matching technique was 
found to be efﬁcient in matching different classes of antipsychotic users. Although the 
efﬁciency of matching methods could differ based on the study sample and availability 
of covariates, a priori criteria can be useful in selecting the most appropriate matching 
technique.
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OBJECTIVES: To estimate the effectiveness of statin+ﬁbrate combination-therapy 
versus statin-monotherapy on cardiovascular disease(CVD) occurrence in subjects 
with type II diabetes in a managed care setting using appropriate econometric models 
dealing with selection bias in nonlinear settings. METHODS: Combination-therapy-
group and monotherapy-group were identiﬁed among subjects with type II diabetes 
with two-years intake period(7/1/2002–6/30/2004) and three-years follow-up using 
administrative claims from a US health plan covering four million lives. Outcomes 
measure was CVD-occurrence. A univariate-probit model was developed to evaluate 
adjusted CVD-risk difference between groups. To control for selection bias, we used 
propensity score(PS) and instrumental variable(IV) method. To deal with nonlinear 
outcomes, we built two-stage-probit model with IV method using two-stage-residual-
inclusion estimation. We used physician prescribing preference as the instrument. To 
test the validity of the instrument, we tested for the correlation between the instrument 
and treatment indicator using standard t-test. To check whether it is valid to exclude 
the instrument from the main equation, Wald-test was performed. Stock-and-Yogo 
test was used to check the weak instrument issue. To test the endogeneity of treatment 
indicator, we performed Hausman-test. RESULTS: Adjusting for age, gender, prior-
CVD, CVD-related pharmacy-costs, Elixhauser-comorbidity, and diabetes with com-
plication, combination-therapy-group experienced 9.1% less CVD compared with 
monotherapy-group at the mean of covariates(P = 0.008). The results from probit and 
PS model were similar. For the IV model, speciﬁcation-tests indicated that the validity 
of the instrument was satisﬁed. However, Hausman-test implied that treatment-indi-
cator was not endogenous(p = 0.172). CONCLUSIONS: To deal with nonlinearity 
issues when using IV method, we employed two-stage residual-inclusion estimation. 
Since we failed to identify selection bias which may be due to untestable assumptions 
and treatment effect heterogeneity, a univariate-probit model or PS model was used 
to draw conclusions. In diabetics after adjusting for known baseline differences, CVD-
risk was signiﬁcantly lower among subjects with statin+ﬁbrate combination-therapy 
compared with those with statin-monotherapy.
PODIUM SESSION II: HEALTH CARE TRENDS
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OBJECTIVES: After the patent expires for a branded pharmaceutical, generic drug 
companies sell bioequivalent versions of the drug, leading to lower prices and reduced 
expenditures for payers. The objectives of this study were to 1) predict the number of 
generic-company entrants in the market, and, 2) determine the trend in drug price 
post-entry based on drug, market, and ﬁrm characteristics. METHODS: Using the 
national summary ﬁle of Medicaid outpatient drug utilization maintained by the 
Centers for Medicare and Medicaid Services, quarterly utilization and expenditure 
data from 1991–2008 were extracted for 40 drugs that experienced initial generic 
entry between 1992 and 2004. Generic relative price (GRP) was constructed as reim-
bursement per unit for a speciﬁc ﬁrm and quarter divided by average reimbursement 
per unit over the year before entry. Least-squares regression models were estimated 
on the panel data to explain number of entrants, GRP, and average GRP across ﬁrms 
(AGRP). RESULTS: After patent expiration, the number of generic-ﬁrm entrants 
ranged from 1 to 25. Signiﬁcant (p < 0.0001) predictors for number of entrants 
included pre-entry market size, market growth, number of quarters since entry, and 
administration form (oral, injectable, or topical). The number of ﬁrms had a statisti-
cally signiﬁcant (p < 0.0001), nonlinear negative effect on GRP and AGRP. With the 
addition of one more generic ﬁrm, GRP is expected to fall by 0.018; AGRP is expected 
to fall by 0.053. High demand, as indicated by high post-entry expenditures, had a 
statistically signiﬁcant (p < 0.0001) positive effect on both GRP and AGRP. Many of 
the ﬁrm-speciﬁc effects were signiﬁcant (p < 0.0001). CONCLUSIONS: Medicaid can 
generally look forward to cost savings following generic entry. However, a small initial 
market size or a drop in demand following entry prohibits Medicaid from obtaining 
cost relief. Differences in pricing strategies across ﬁrms were indicated by the variation 
in GRP across manufacturers.
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RECENT TRENDS IN EMPLOYER HEALTH CARE SPENDING BY DISEASE
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OBJECTIVES: Efforts to “bend the cost curve” in US health care need to be informed 
by a differentiated view of health care spending by disease. We highlight the impor-
tance of particular diseases based on level and rate of growth of spending. METHODS: 
National health care spending by employers for all services and for prescription drugs 
was estimated using claims data from employer sponsored health plans from 2004 
and 2008. Data were projected using sampling weights derived from the Medical 
Expenditure Panel Survey and trends in spending were calculated as compound annual 
growth rates (CAGR). Claims were assigned to disease-speciﬁc episodes using the 
Thomson Reuters Medical Episode Grouper (MEG). RESULTS: Annual spending data 
were analyzed for 122 employers with 11.5 million covered lives in 2004 and 143 
employers with 15.6 million covered lives in 2008. Overall spending grew at 8.6% 
per annum while prescription drug spending grew at 10.8%. Musculoskeletal condi-
tions were the most important body system, representing 18% of all spending and 
growing at 11% per year, well above average. Several speciﬁc conditions had total 
spending growth rates of 15%, including osteoarthritis of the spine, multiple sclerosis, 
and prostate cancer. Preventive health services also grew at 15%. The single disease 
with the largest total spending, angina pectoris, grew at less than 1% per year. Drug 
spending grew the fastest for Crohn’s disease (25%), epilepsy (23%), and multiple 
sclerosis (19%). Spending for type 2 diabetes drugs was particularly important, as it 
represented 11% of all drug spending and grew at 17% per year, well above average. 
CONCLUSIONS: Major drivers of recent growth in employer health care spending 
are conditions related to obesity, including musculoskeletal and endocrine conditions. 
The highest rates of drug spending were observed in conditions where biologic thera-
pies are becoming standard of care.
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OBJECTIVES: While generic drug use has become more common with the availability 
of generic alternatives to the many high volume branded products, the rate at which 
generic drugs have displaced branded counterparts is not well understood, particularly 
when time-release (TR) brands are introduced within a similar timeframe. We exam-
ined the uptake of generic drugs with respect to products and classes in conjunction 
with the uptake of time-release formulations of branded products to determine the 
impact of generic uptake on branded drugs, particularly when a branded time-release 
formulation is launched prior to generic competition. METHODS: SSRIs, atypical 
antipsychotics, nonbenzodiazepines as well as azythromycin were selected as case 
classes and products. From 1995 to 2009 the volume of prescriptions were collected 
monthly using SDI’s VONA databases and grouped according to branded and generic 
sales by active molecule. RESULTS: Among SSRIs, brands that launched TR branded 
products at least one-year prior to the launch of the original formulation generic, such 
as paroxetine, saw less erosion of the total brand than those with TR launch less than 
one year or no TR launch. Similarly, among nonbenzodiazepines, early launch of TR 
